Background

Propofol has been shown to produce relaxation of preconstricted airway smooth muscle. Although the inhibition of calcium mobilization is supposed to be the major mechanism of action, the whole picture of the mechanisms is not completely clear.

Methods

Contractile response was performed using canine tracheal rings. The effects of propofol on carbachol-induced mobilization of intracellular Ca2+ and phosphoinositide hydrolysis were measured using cultured canine tracheal smooth muscle cells by monitoring fura-2 signal and assessing the accumulation of [3H]-inositol phosphates. To detect the effect of propofol on muscarinic receptor density and affinity, [3H]N-methyl-scopolamine was used as a radioligand for receptor binding assay.

Results

Pretreatment with propofol shifts the concentration-response curves of carbachol-induced smooth muscle contraction to the right in a concentration-dependent manner without changing the maximal response. Propofol not only decreased the release of Ca2+ from internal stores but also inhibited the calcium influx induced by carbachol. In addition, carbachol-induced inositol phosphate accumulation was attenuated by propofol; the inhibitory pattern was similar to the contractile response. Moreover, propofol did not alter the density of muscarinic receptors. The dissociation constant value was not altered by pretreatment with 100 microM propofol but was significantly increased by 300 microM (propofol, 952+/-229 pM; control, 588+/-98 pM; P<0.05).

Conclusions

Propofol attenuates the muscarinic receptor-mediated airway muscle contraction. The mechanism underlying these effects was attenuation of inositol phosphate generation and inhibition of Ca2+ mobilization through the inhibition of the receptor-coupled signal-transduction pathway.

PROPOFOL (2,6-di-isopropylphenol), a widely used intravenous anesthetic with the characteristics of rapid onset, short duration of action, and rapid elimination, 1is reported to antagonize fentanyl-induced bronchoconstriction during surgery, 2and to inhibit postoperative bronchospasm in patients with hyperreactive airway disease. 3In addition, in vitro , propofol has been shown to produce relaxation of tracheal smooth muscle (TSM) with spontaneous tone or contraction induced by acetylcholine, carbachol, histamine, prostaglandin F2α, and potassium. 4–6It is well known that Ca2+plays an important role in the contraction of smooth muscle. The regulation of intracellular Ca2+([Ca2+]i) is integrated by several mechanisms located on plasma membrane and intracellular organelles. 7These include the Ca2+release from the internal store and influx of extracellular Ca2+. In vascular smooth muscle cells, propofol produced a relaxing effect through the inhibition of Ca2+mobilization. 8Furthermore, propofol has been shown to inhibit voltage-dependent Ca2+channels in porcine TSM cells. 9 

In mammalian airway, the parasympathetic nervous system, a predominant neural pathway, plays an important role in the regulation of airway diameter and resistance to airflow. 10Acetylcholine released from parasympathetic nerve endings stimulates the smooth muscle contraction via  its binding to muscarinic cholinergic receptors (mAChRs). 11Following the stimulation of M3receptors on airway smooth muscle, 12–14phospholipase C is activated via  a guanosine 5′-triphosphate–binding protein, which hydrolyzes phosphoinositide, leading to the formation of inositol-1,4,5-trisphosphate (IP3). In rat aortic smooth muscle, propofol has been shown to inhibit the IP3production induced by endothelin-1 and arginine vasopressin. 8Thus, propofol might attenuate the IP3-induced Ca2+mobilization.

The present study therefore was undertaken to investigate how propofol might modulate the pharmacological properties of mAChRs, inositol phosphate (IP) accumulation, Ca2+mobilization, and subsequently the contraction of airway smooth muscle.

Animals 

Mongrel dogs of either sex, 20–30 kg, purchased from a local supplier, were used throughout this study. Dogs were housed indoors in the Laboratory of Animal Resource Center at Chang Gung University under automatically controlled temperature and light cycle and fed with standard laboratory chow and tap water ad libitum . The procedures used in this study have been reviewed and approved by the University's animal use committee, indicating that the procedures are in accord with the institutional guidelines for animal use. Dogs were anesthetized with ketamine (6 mg/kg intramuscular), and the lungs were ventilated mechanically via  an endotracheal tube. The tracheae were surgically removed.

Contractile Response 

The removed trachea, about 20 cm long from larynx to bifurcation, was quickly transferred to oxygenated (95% O2plus 5% CO2) Krebs-Henseleit solution of the following composition (in mM): NaCl 117, KCl 4.7, MgSO41.1, KH2PO41.2, NaHCO320, CaCl22.4, glucose 1, HEPES 20. The trachea was opened by cutting the cartilage rings opposite to the smooth muscle. The muscle was cleaned in two steps. The initial step in each dissection involved removal of the epithelium and submucosal tissue with forceps. The connective tissue on the serosal surface was carefully cleaned. In order to hook the muscle strips to the transducer, the section of cartilage up to the point of insertion of the muscle was maintained. Then the trachea was cut into separate individual rings. The TSM strips were mounted in an organ bath containing physiologic solution with the composition (in mM): NaCl 125, KCl 5, MgCl22, NaH2PO40.5, NaHCO35, CaCl21.8, glucose 10, HEPES 10, and gases with 95% O2plus 5% CO2at 37°C. The TSM strips were equilibrated in physiologic solution for 60 min with three changes of physiologic solution and maintained under an optimal tension of 1.0 g. Contraction was recorded isometrically via  a force-displacement transducer connected to a recorder (BIOPAC System, Goleta, CA). To determine the effects of propofol on contraction induced by carbachol, TSM strips were initially stimulated by 50 mM KCl, and the tensions were defined as the maximal contraction. Following washing out and equilibration, the TSM strips were divided into three groups, incubated 30 min with dimethylsulfoxide (DMSO) or 100 μM or 300 μM propofol (dissolved in DMSO), respectively. Cumulative concentration response curves for carbachol (10 nM to 1 mM) were constructed. Results are expressed as a percentage of maximal response induced by 50 mM KCl.

Isolation of Tracheal Smooth Muscle Cells 

Tracheal smooth muscle cells (TSMCs) were isolated according to the method described previously. 15,16In brief, the smooth muscle was dissected, minced, and transferred to the dissociation medium containing 0.1% collagenase IV, 0.025% deoxyribonuclease I, and 0.025% elastase IV and antibiotics (100 U/ml penicillin, 100 μg/ml streptomycin, 50 μg/ml gentamicin and 2.5 μg/ml fungizone) in a solution composed of (in mM): NaCl 137, KCl 5, CaCl21.1, NaHCO320, NaH2PO41, glucose 11, HEPES 25, p  H 7.4. The tissue pieces were gently agitated at 37°C in a rotary shaker for 1 h; the released cells were collected and the residue was digested in the same fresh enzyme solution for an additional hour at 37°C. All released cells were collected and washed twice with Dulbecco's modified Eagle's medium (DMEM) and Ham's nutrient mixture F-12 medium (1:1, v/v). The cells, suspended in DMEM/F-12 containing fetal bovine serum (FBS) 10%, were preplated onto petri dishes (60 mM) and incubated at 37°C for 1 h to remove fibroblasts. The cells then were counted and diluted with DMEM/F-12 to 2 × 105cells/ml. The cells, suspended in DMEM/F-12 containing 10% FBS, were plated onto 24-well (0.5 ml per well), 12-well (1 ml per well), or six-well (2 ml per well) culture plates containing glass coverslips coated with collagen for receptor binding assay, IP accumulation, and Ca2+measurement, respectively. The culture medium was changed after 24 h and then changed every 3 days. After 5 days in culture, the cells were changed to DMEM/F-12 containing FBS (1%) for 24 h at 37°C. Then the cells were cultured in DMEM/F-12 containing FBS (1%) supplemented with insulin-like growth factor (10 ng/ml) and insulin (1 μg/ml) for 12–14 days.

To characterize the isolated and cultured TSMCs and to exclude the possibility of contamination by epithelial cells and fibroblasts, the cells were identified by an indirect immunofluorescent staining method using a monoclonal antibody of light chain myosin. 17Over 95% of the cells were smooth muscle cells.

Accumulation of Inositol Phosphates 

The effect of propofol on the hydrolysis of phosphoinositol was assayed by monitoring the accumulation of [3H]-labeled IPs as described by Berridge et al.  18Cultured TSMCs were incubated with 5 μCi/ml of myo-[2-3H]-inositol at 37°C for 2 days. TSMCs were washed two times with phosphate-buffered saline and incubated in Krebs-Henseleit buffer (Krebs-Henseleit solution, p  H 7.4) containing (in mM): NaCl 117, MgSO41.1, KH2PO41.2, NaHCO320, CaCl22.4, glucose 1, HEPES 20, and LiCl 10 at 37°C for 30 min. Propofol was added 30 min before the addition of the agonist. Control group was treated with the same concentration of DMSO. After the addition of carbachol, incubation was continued for another 60 min. Reactions were terminated by addition of 5% perchloric acid followed by sonication and centrifugation at 3,000g  for 15 min.

The perchloric acid soluble supernatants were extracted four times with ether, neutralized with potassium hydroxide, and applied to a column of AG1-X8, formate form, 100–200 mesh (Bio-Rad, Hercules, CA). The resin was washed successively with 5 ml of 60 mM ammonium formate and 5 mM sodium tetraborate to eliminate free myo-[3H]-inositol and glycerophosphoinositol, respectively. The fraction of total IPs was eluted with 5 ml of 1 M ammonium formate and 0.1 M formic acid. The amount of [3H]-IPs was determined in a radiospectrometer (Beckman LS5000TA, Fullerton, CA).

[3H]N-Methyl Scopolamine Binding Assay 

For detection of the effect of propofol on muscarinic receptor density or affinity on TSMCs, [3H]N -methyl-scopolamine ([3H]NMS) was used as a radioligand. Total number of cell-surface [3H]NMS binding sites per well was determined by incubating cells in phosphate-buffered saline containing various concentrations of [3H]NMS ranging from 20 to 1,000 pM. nonspecific binding of [3H]NMS was determined in the presence of 1 μM atropine sulfate. Binding reactions were incubated at 37°C for 45 min and terminated by removing the reaction mixture and washing the cells three times with phosphate-buffered saline. Cells were solubilized in 0.1 N NaOH and scintillation fluid and counted in a radiospectrometer. The dissociation constant (KD) and total receptor density (Bmax) were calculated by GraphPad Prism (GraphPad Software, San Diego, CA).

Measurement of Intracellular Ca2+Level 

[Ca2+]iwas measured in confluent monolayers with the calcium-sensitive dye fura-2/AM as described by Grynkiewicz et al.  19Upon confluence, the cells were cultured in DMEM/F-12 with 1% FBS 1 day before measurements were taken. The monolayers were covered with 1 ml of DMEM/F-12 with 1% FBS containing 5 μM fura-2/AM and incubated at 37°C for 45 min. At the end of the loading period, the coverslips were washed twice with physiologic buffer as described in Contractile Response. The cells were incubated in the same buffer with or without propofol for another 30 min to complete dye deesterification. The coverslip was inserted into a quartz cuvette at an angle of approximately 45 degrees to the excitation beam and placed in the thermostatted holder of an SLM 8000C spectrofluorometer (SLM, Urbana, IL). Continuous stirring was achieved with a magnetic stirrer.

Fluorescence of Ca2+-bound and unbound fura-2 was measured by rapidly alternating the dual excitation wavelengths between 340 and 380 nm and electronically separating the resultant fluorescence signals at an emission wavelength of 510 nm. The autofluorescence of each monolayer was subtracted from the fluorescence data. The ratios of the fluorescence at the two wavelengths were computed and used to calculate changes in [Ca2+]i. The ratios of maximum and minimum fluorescence of fura-2 were determined by the addition of ionomycin (10 μM) in the presence of Phocal buffer containing 5 mM Ca2+and by adding 5 mM EGTA at p  H 8 in Ca2+-free Phocal buffer, respectively. The KDof fura-2 for Ca2+was assumed to be 224 nM. 19 

Materials 

Propofol was purchased from Aldrich (Milwaukee, WI). DMEM and FBS were purchased from J.R. Scientific (Woodland, CA). Myo-[2-3H]inositol (18 Ci/mmol) and [3H]N -methyl scopolamine (84 Ci/mmol) were obtained from Amersham (Buckinghamshire, UK), and DMEM-inositol free medium was from Life Technologies (Gaithersburg, MD). Fura-2/AM was ordered from Molecular Probes (Eugene, OR) and enzyme and other chemicals from Sigma (St. Louis, MO).

Statistical Analysis 

Concentration–effect curves were fitted by GraphPad Prism. EC50values were estimated by the same program and expressed as the mean pEC50(−log EC50, expressed in M)± SD. Data were expressed as the mean ± SD and analyzed with the Student t  test or one-way analysis of variance as indicated at a 0.05 level of significance. The Bonferroni post-test was performed if one-way analysis of variance was significant.

Effect of Propofol on the Contraction of TSM Strips 

To assess the effect of propofol on modulation of the constrictor response to cholinergic stimulation, concentration–response relationships to carbachol were compared among TSM strips pretreated with DMSO (control), 100 μM propofol, and 300 μM propofol. The pEC50values were 7.12 ± 0.26, 6.75 ± 0.21, and 6.24 ± 0.10, respectively (fig. 1). Compared with the controls, propofol of either dose significantly decreased the pEC50(P < 0.05) and shifted the concentration–response curves of carbachol to the right in a dose-dependent manner. However, the maximal responses to carbachol were slightly but not significantly attenuated by 100 μM or 300 μM propofol with the values of 137.9 ± 16.8% and 128.8 ± 13.9%, respectively, compared with the value of 148.1 ± 18.4% obtained in controls.

Effects of Propofol on Carbachol-induced Ca2+Mobilization 

Calcium ions play a key role in the contraction of TSMCs. The activation of mAChRs results in the release of Ca2+from sarcoplasmic reticulum and the entry of extracellular Ca2+. In our previous study, carbachol produced a biphasic [Ca2+]ichange in the presence of extracellular Ca2+, which displayed an initial transient peak and a sustained plateau phase. 13 

To check whether propofol attenuates the increase of [Ca2+]iinduced by carbachol, the effect of propofol on the concentration–response curve of carbachol was examined. The confluent coverslips with TSMC monolayers were pretreated with DMSO (control) or propofol (100 μM or 300 μM) for 30 min, and the initial peak of [Ca2+]iinduced by carbachol was measured. Concentration–response curves for carbachol (10 nM to 0.1 mM) were constructed. Figure 2A–Cshows the traces of carbachol-induced [Ca2+]ichange in various concentrations. As displayed in figure 2D, the pEC50values for carbachol were 6.85 ± 0.58, 5.93 ± 0.18, 4.55 ± 1.33 in the control and propofol (100 μM and 300 μM)–treated TSMCs, respectively, with corresponding maximal increase in [Ca2+]iof 132.4 ± 22.7, 91.0 ± 24.5, and 26.1 ± 20.4 nM, respectively. Compared with the controls, maximal response and pEC50to carbachol were significantly attenuated (P < 0.05) by either dose of propofol. Accordingly, propofol shifted the dose—response curve for carbachol to the right in a dose-dependent manner.

To further elucidate the mechanism of the attenuation of [Ca2+]iincrease, the effect of propofol on Ca2+release from internal stores and the influx of extracellular Ca2+was examined. The confluent coverslips with TSMC monolayers (different cells from different dogs) were pretreated with DMSO (control) or propofol (1 μM to 300 μM) for 30 min. The initial peak of [Ca2+]iinduced by carbachol (100 μM) was measured in the absence of extracellular Ca+. Then, Ca2+was added with the final extracellular Ca2+concentration at 1.8 mM, and [Ca2+]iwas measured. Figure 3Ashows the trace of carbachol-induced [Ca2+]iincrease in the absence of extracellular Ca2+before 300 s, and the presence of Ca2+when it was added at 300 s. The maximal increased [Ca2+]imeasured in the absence of extracellular Ca2+represents its release from internal store, that is, sarcoplasmic reticulum, and [Ca2+]imeasured in the readdition of Ca2+represents Ca2+influx from extracellular source. Pretreatment of TSMCs with propofol at concentrations of 10, 100, and 300 μM significantly attenuated carbachol-induced Ca2+release from internal stores, with maximal responses at 51.1 ± 8.5, 45.3 ± 6.9, 30.3 ± 7.6 nM, respectively, as compared with control cells at 73.7 ± 11.5, P < 0.05 (fig. 3B). Following the measurement of transient [Ca2+]i, Ca2+(1.8 mM) was readded to measure its influx into TSMCs. Propofol alone had no effect on [Ca2+]i(data not shown). These results showed that pretreatment of theses cells with 10, 100, and 300 μM propofol significantly blocked carbachol-induced Ca2+influx, with maximal responses at 71.5 ± 20.0, 67.6 ± 17.8, and 56.4 ± 19.5 nM, respectively, as compared with control cells at 124.4 ± 26.4 nM, P < 0.05 (fig. 3B). However, at the lower concentration 1 μM of propofol did not affect carbachol-induced Ca2+response in TSMCs.

Effect of Propofol on Carbachol-induced IP Accumulation 

Propofol attenuates the Ca2+release induced by carbachol, whereas Ca2+release is determined by the binding of IP3to its receptors on the sarcoplasmic reticulum. 20To determine whether propofol interferes with the production of IP3, the IP accumulation induced by carbachol was measured in the absence or presence of propofol (100 μM and 300 μM). As shown in figure 4, propofol significantly shifted the concentration response curves of carbachol to the right in a dose-dependent manner. The maximal response for carbachol was also inhibited by propofol. The pEC50values, 4.20 ± 0.26 and 4.00 ± 0.22, for carbachol-induced IP accumulation were significantly attenuated in the presence of 100 and 300 μM propofol, respectively, as compared with control (4.90 ± 0.12, P < 0.05).

Effect of Propofol on [3H]NMS Binding 

The finding that propofol inhibited the production of IP indicated that it may interfere with the receptor-coupled signal transduction. The action site may be located at the muscarinic receptors. To examine whether propofol alters Bmaxor KDfor the muscarinic receptor, a receptor binding assay was performed in TSMCs treated with propofol for 30 min, using [3H]NMS as a radioligand. Figure 5Ashows the saturation binding isotherm derived from one of five experiments. Scatchard plot analysis of the specific bound [3H]NMS is displayed in figure 5B. The x-intercept of the least-squares fit to Scatchard plot is a measure of Bmax, and the negative reciprocal of the slope is the KD. The Bmaxand KDvalues are summarized in table 1. These results demonstrate that pretreatment of TSMCs with both concentrations of propofol does not significantly change the Bmaxof mAChRs. Similarly, the KDvalue was not significantly altered by pretreatment with 100 μM propofol. However, propofol concentration at 300 μM significantly attenuated the affinity of mAChR for [3H]NMS binding (propofol, 952 ± 229 pM; control, 588 ± 98 pM;P < 0.05).

It has been well known that parasympathetic nervous system forms the predominant neural pathway and plays an important role in the regulation of airway diameter and resistance to airflow in mammalian airway. 10Neurotransmitter acetylcholine released from parasympathetic nerve endings stimulates the contraction of airway smooth muscle via  the activation of guanosine 5′-triphosphate–binding protein-coupled signal-transduction pathway. 15,21The activation of G-protein further activates phospholipase C, which hydrolyzes phosphoinositide, leading to the formation of IP3and diacylglycerol. 22IP3in turn stimulates the release of calcium ions from its intracellular stores. 23Diacylglycerol translocates the cytosolic protein kinase C to the cell membrane, and the activation of protein kinase C further phosphorylates substrates on cell membrane, resulting in the opening of calcium channel. 24,25In addition, the activation of receptors also results in the opening of calcium channels via  the guanosine 5′-triphosphate–binding protein or membrane depolarization. 26,27The increased [Ca2+]iactivates myosin light chain kinase through a calmodulin-dependent mechanism. 28The active kinase phosphorylates myosin light chain, leading to initiation of contraction. Thus, alteration in the components of the receptor-coupled signal-transduction pathway may be associated with the change in the tension of airway smooth muscle. In the present study, these results demonstrated that propofol attenuated the contraction mediated by mAChRs in this tissue. The mechanism underlying the relaxant effects might be caused inhibition of Ca2+mobilization and attenuation of the generation of IPs via  the inhibition of the receptor-coupled signal-trasduction pathway.

In the current study, our results regarding the relaxant effect of propofol on airway smooth muscle (fig. 1) are consistent with other studies either in vivo  2,3or in vitro . 4–6Because Ca2+plays an important role in the contraction of smooth muscle, we examine the effect of propofol on the Ca2+mobilization and IP accumulation in cultured TSMCs induced by carbachol. In our previous study, a cell-culture model of TSMCs expressing functional mAChRs was shown to be a useful method for studying the physiologic function of airway smooth muscle. 29The density of mAChRs expressed in primary culture of TSCMs was approximately 75% of that in freshly isolated TSMCs. Furthermore, carbachol produced a biphasic [Ca2+]ichange in the presence of extracellular Ca2+, which displayed an initial transient peak and a sustained plateau phase. 13In contrast, in the absence of extracellular Ca2+, carbachol induced a smaller transient peak, and the sustained plateau phase was not observed. This represents the Ca2+release from the internal store in the absence of extracellular Ca2+. Readdition of Ca2+to TSMCs after stimulation with carbachol in the absence of extracellular Ca2+caused a sustained increase in [Ca2+]i, which was defined as the Ca2+influx from extracellular source. In the present study, we demonstrated that propofol not only attenuated the Ca2+mobilization but also decreased the pEC50in the concentration–response curves for carbachol (fig. 2), consistent with the results obtained from freshly isolated rat TSMCs. 6We further examined the effect of propofol on Ca2+release from internal store and the influx of extracellular Ca2+. Propofol was shown to attenuate not only the Ca2+release from SR but also the influx of extracellular Ca2+(fig. 3). The inhibition of Ca2+influx may be caused by blockade of voltage-dependent Ca2+channels as shown in porcine TSM. 9In addition, in rat TSM, Quedraogo et al. 6also demonstrated that propofol inhibits KCl-induced [Ca2+]iincrease, which indicates the inhibition of Ca2+influx through voltage-dependent Ca2+channels. It is also the case in other cell types that propofol inhibits the voltage-dependent Ca2+channels. 8,30–32Taken together, our results are consistent with these studies that propofol might inhibit voltage-dependent Ca2+channels and attenuate Ca2+influx. 8,13,30–32In addition, Ca2+homeostasis is integrated by several mechanisms located on the plasma membrane and inside of cells. Propofol may also influence the Ca2+–adenosine triphosphatase pumps that move Ca2+both to the internal stores and outside of the cells. Because of the limitations of experimental techniques, we did not make an attempt to differentiate the effect of propofol on these components in this study. The effect of propofol on these pump activities needs to be further investigated.

Ca2+release from intracellular stores is regulated by two mechanisms: IP3-induced Ca2+release and Ca2+-induced Ca2+release. 20,33We further examined the effects of propofol on the production of IPs and demonstrated that propofol attenuates the IP production induced by carbachol (fig. 4), which is associated with inhibition of Ca2+release (fig. 3). It seems unlikely that propofol depletes the Ca2+content of SR, because it does not alter the basal level of [Ca2+]i. In rat aortic smooth muscle, propofol has been shown to inhibit the IP3production induced by endothelin-1 and arginine vasopressin, 8which further supports our observation. As mentioned previously, IP3is a second messenger in the M3receptor-coupled signaling pathway. This finding also indicates that propofol may interfere with the receptor-coupled signal-transduction pathway.

To locate the site of action, the effect of propofol on the Bmaxand KDof muscarinic receptors was examined. It was shown that propofol did not alter the Bmax, which was consistent with the results that propofol had no effect on endothelin-1 binding to its receptor. 34In addition, propofol has been shown to attenuate histamine-induced contraction of human TSM and acetylcholine-induced Ca2+mobilization in rat TSMCs. 6These results suggest that the effect of propofol is not restricted to mAChR activation. However, at the concentration of 300 μM, propofol significantly decreased the binding affinity of mAChRs. These data indicate that at the concentration of 100 μM, the action site is downstream to agonist–receptor binding, however, at higher concentration, the receptor-binding dynamic was also altered. Propofol may interfere with the components of receptor–G-protein–phospholipase C pathway; however, the precise site of action is not known. These findings demonstrated that the inhibition of receptor–G-protein–phospholipase C pathway by propofol was involved in the inhibition of smooth muscle contraction.

In an in vivo  study of a bolus intravenous dose of 14C-propofol (7–10 mg/kg) to dogs, propofol concentrations were 4–16 μg/ml (22–88 μM) at 2 min. Duration of sleep ranged from 5 to 8 min. 35However, the free plasma concentration of propofol was less than 8.8 μM, because of its strong protein-binding properties (>90%). At anesthetic level, the concentration of propofol in whole brain (225 μM) was 7.8 times that in plasma (29 μM) 30 min after intravenous infusion of propofol at 60 mg · kg−1· h−1. 36The effective concentration in plasma is usually less than 1 μM, because propofol is a highly protein-binding agent. 37Thus, the concentrations used in this study are one or two orders of magnitude higher than achieved in vivo  under clinical conditions. However, there are no data related to the tissue:plasma or tissue:blood ratio in canine TSM. The results in the contractile-response experiment revealed that propofol did not reduce the maximal tension induced by carbachol (fig. 1). However, propofol significantly attenuated the maximal IP accumulation and [Ca2+]ichange induced by carbachol (fig. 2D and fig. 4). This discrepancy may result from the difference between freshly isolated TSM tissues and cultured smooth muscle cells. In addition, although less likely, it may be caused by the more complete distribution of propofol in cultured cells than in intact tissues. Moreover, higher concentrations of propofol may be needed to across the connective tissues served as a permeability barrier to reach smooth muscle. This may be the reason why 10 μM propofol attenuates carbachol-induced increase in [Ca2+]ibut has no effect on contractile response. However, all the inhibitory effects of propofol are obtained at high concentrations, and the clinical relevance is not clear.

In conclusion, this study examined the relaxant effect of propofol on canine airway smooth muscle and elucidated the mechanisms of its action. These results demonstrated that (1) propofol attenuated the contraction induced by carbachol in a concentration-dependent manner;(2) propofol attenuated not only the IP3-induced Ca2+release from internal store but also the influx of external Ca2+;(3) carbachol-induced IP3production was also attenuated by propofol, indicating that propofol interfered with the signal transduction pathway; and (4) propofol at a higher concentration (300 μM) decreased the binding affinity of muscarinic receptor but did not alter the receptor density. Taken together, propofol inhibited the carbachol-induced contraction of canine TSM. The mechanisms underlying this inhibition may involve the inhibition of the muscarinic receptor–mediated signal transduction pathway.

1.
Sebel PS, Lowdon JD: Propofol: A new intravenous anesthetic. A NESTHESIOLOGY 1989; 71: 260–77
2.
Cigarini I, Bonnet F, Lorino AM, Harf A, Desmonts JM: Comparison of the effects of fentanyl on respiratory mechanics under propofol or thiopental anaesthesia. Acta Anaesth Scand 1990; 34: 253–56
3.
Pedersen CM: The effect of sedation with propofol on postoperative bronchoconstriction in patients with hyperreactive airway disease. Intensive Care Med 1992; 18: 45–6
4.
Pedersen CM, Thirstrup S, Nielsen-Kudsk JE: Smooth muscle relaxant effects of propofol and ketamine in isolated guinea-pig trachea. Eur J Pharmacol 1993; 238: 75–80
5.
Cheng EY, Mazzeo AJ, Bosnjak ZJ, Coon RL, Kampine JP: Direct relaxant effects of intravenous anesthetics on airway smooth muscle. Anesth Analg 1996; 83: 162–8
6.
Ouedraogo N, Roux E, Forestier F, Rossetti M, Savineau JP, Marthan R: Effects of intravenous anesthetics on normal and passively sensitized human isolated airway smooth muscle. A NESTHESIOLOGY 1998; 88: 317–26
7.
Horowitz A, Menice CB, Laporte R, Morgan KG: Mechanisms of smooth muscle contraction. Physiol Rev 1996; 76: 967–1003
8.
Xuan YT, Glass PS: Propofol regulation of calcium entry pathways in cultured A10 and rat aortic smooth muscle cells. Br J Pharmacol 1996; 117: 5–12
9.
Yamakage M, Hirshman CA, Croxton TL: Inhibitory effects of thiopental, ketamine, and propofol on voltage-dependent Ca2+channels in porcine tracheal smooth muscle cells. A NESTHESIOLOGY 1995; 83: 1274–82
10.
Barnes PJ: Neural control of human airways in health and disease. Am Rev Resp Dis 1986; 134: 1289–314
11.
Colebatch HJH, Halmagyi KFJ: Effect of vagotomy and vagal stimulation on lung mechanics and circulation. J Appl Physiol 1963; 18: 881–7
12.
van Koppen CJ, Rodrigues DMJ, Beld AJ, Hermanussen MW, Lam M ers JW, van Ginneken CA: Characterization of the muscarinic receptor in human tracheal smooth muscle. Naunyn-Schmiedebergs Arch Pharmacol 1985; 331: 247–52
13.
Yang CM, Yo YL, Wang YY: Intracellular calcium in canine cultured tracheal smooth muscle cells is regulated by M3muscarinic receptors. Br J Pharmacol 1993; 110: 983–8
14.
Brichant JF, Warner DO, Gunst SJ, Rehder K: Muscarinic receptor subtypes in canine trachea. Am J Physiol 1990; 258: L349–54
15.
Yang CM, Chou SP, Sung TC: Muscarinic receptor subtypes coupled to generation of different second messengers in isolated tracheal smooth muscle cells. Br J Pharmacol 1991; 104: 613–8
16.
Yang CM, Chou SP, Sung TC, Chien HJ: Regulation of functional muscarinic receptor expression in tracheal smooth muscle cells. Am J Physiol 1991; 261: C1123–9
17.
Gown AM, Vogel AM, Gordon D, Lu PL: A smooth muscle-specific monoclonal antibody recognizes smooth muscle actin isozymes. J Cell Biol 1985; 100: 807–13
18.
Berridge MJ, Dawson RM, Downes CP, Heslop JP, Irvine RF: Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem J 1983; 212: 473–82
19.
Grynkiewicz G, Poenie M, Tsien RY: A new generation of Ca2+indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440–50
20.
Somlyo AV, Bond M, Somlyo AP, Scarpa A: Inositol trisphosphate-induced calcium release and contraction in vascular smooth muscle. Proc Natl Acad Sci USA 1985; 82: 5231–35
21.
Lucchesi PA, Scheid CR, Romano FD, Kargacin ME, Mullikin-Kilpatrick D, Yamaguchi H, Honeyman TW: Ligand binding and G protein coupling of muscarinic receptors in airway smooth muscle. Am J Physiol 1990; 258: C730–8
22.
Berridge MJ, Irvine RF: Inositol phosphates and cell signalling. Nature 1989; 341: 197–205
23.
Ehrlich BE, Watras J: Inositol 1,4,5-trisphosphate activates a channel from smooth muscle sarcoplasmic reticulum. Nature 1988; 336: 583–6
24.
Nishizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988; 334: 661–5
25.
Murray RK, Kotlikoff MI: Receptor-activated calcium influx in human airway smooth muscle cells. J Physiol 1991; 435: 123–44
26.
Kamishima T, Nelson MT, Patlak JB: Carbachol modulates voltage sensitivity of calcium channels in bronchial smooth muscle of rats. Am J Physiol 1992; 263: C69–77
27.
Godfraind T, Miller R, Wibo M: Calcium antagonism and calcium entry blockade. Pharmacol Rev 1986; 38: 321–416
28.
van Breemen C, Saida K: Cellular mechanisms regulating [Ca2+]ismooth muscle. Annu Rev Physiol 1989; 51: 315–29
29.
Yang CM, Chou SP, Sung TC, Chien HJ: Regulation of functional muscarinic receptor expression in tracheal smooth muscle cells. Am J Physiol 1991; 261: C1123–9
30.
Yang CY, Wong CS, Yu CC, Luk HN, Lin CI: Propofol inhibits cardiac L-type calcium current in guinea pig ventricular myocytes. A NESTHESIOLOGY 1996; 84: 626–35
31.
Olcese R, Usai C, Maestrone E, Nobile M: The general anesthetic propofol inhibits transmembrane calcium current in chick sensory neurons. Anesth Anal 1994; 78: 955–60
32.
Zhou W, Fontenot HJ, Liu S, Kennedy RH: Modulation of cardiac calcium channels by propofol. A NESTHESIOLOGY 1997; 86: 670–5
33.
Iino M: Calcium-induced calcium release mechanism in guinea pig taenia caeci. J Gen Physiol 1989; 94: 363–83
34.
Tanabe K, Kozawa O, Kaida T, Matsuno H, Niwa M, Ohta S, Dohi S, Uematsu T: Inhibitory effects of propofol on intracellular signaling by endothelin-1 in aortic smooth muscle cells. A NESTHESIOLOGY 1998; 88: 452–60
35.
Simons PJ, Cockshott ID, Douglas EJ, Gordon EA, Knott S, Ruane RJ: Species differences in blood profiles, metabolism and excretion of 14C-propofol after intravenous dosing to rat, dog and rabbit. Xenobiotica 1991; 21: 1243–56
36.
Shyr MH, Tsai TH, Tan PP, Chen CF, Chan SH: Concentration and regional distribution of propofol in brain and spinal cord during propofol anesthesia in the rat. Neurosci Lett 1995; 184: 212–5
37.
Kirkpatrick T, Cockshott ID, Douglas EJ, Nimmo WS: Pharmacokinetics of propofol (diprivan) in elderly patients. Br J Anaesth 1988; 60: 146–50